Sarilumab demonstrated positive efficacy in the Phase III SARIL-RA program, but its lack of differentiation from Actemra will restrict its patient share.
By Christina Vasiliou, Senior Analyst
19 October 2016
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
Datamonitor Healthcare believes that sarilumab’s (Sanofi/Regeneron) lack of differentiation from the first-to-market interleukin (IL)-6 receptor inhibitor, Actemra (tocilizumab; Roche/Chugai), will restrict its patient share, despite having demonstrated positive efficacy in its Phase III SARIL-RA program. Sarilumab demonstrated improvements in methotrexate-inadequate responders in the Phase III SARIL-RA-MOBILITY study, as well as superiority to Humira (adalimumab; AbbVie/Eisai) in the Phase III SARIL-RA-MONARCH study. In addition, sarilumab demonstrated positive efficacy in inadequate responders to tumor necrosis factor inhibition in the Phase III SARIL-RA TARGET study. While leading rheumatologists appear impressed by sarilumab’s clinical trial program in rheumatoid arthritis (RA), they stress that, to date, the IL-6 receptor inhibitor’s clinical performance has been comparable to that of Actemra. Key opinion leaders also note that once launched, sarilumab will also be disadvantaged by the availability of post-marketing data for Actemra and physician’s experience with the brand. Unless sarilumab offers a significant price advantage, Actemra will remain the IL-6 inhibitor of choice in RA.
“Its clinical performance to date looks remarkably similar, not surprisingly, to that of tocilizumab, but it is nice clean data and it is exactly what you would expect for an anti-IL-6 receptor inhibitor…In reality what happens when these new drugs launch, and given that there may be some small safety differences and we do not have a very big safety database compared to say tocilizumab, it will tend to be used later in the treatment paradigm than tocilizumab, in the more refractory patients initially, unless it is priced very, very competitively.”
EU key opinion leader
Datamonitor Healthcare’s RA: pipeline evaluates the clinical and commercial attractiveness of late-phase candidates, providing an assessment of future product positioning and competitiveness in the marketplace.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>